A Phase 1 interventional study of Cariprazine prolonged release tablet A and Cariprazine prolonged release tablet B in Pharmacokinetic Profile, sponsored by Gedeon Richter Plc.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-24.
Sponsored by Gedeon Richter Plc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The investigators are doing this study to compare blood levels and side effects of cariprazine when it's taken as one of two 'slow release' tablets, or as an 'immediate release' capsule. The investigators will also find out if food affects the absorption of cariprazine into the bloodstream after a 'slow release' tablet.
Comparison of blood levels and side effects of cariprazine when it's taken as one of two 'slow release' tablets, or as an 'immediate release' capsule. We'll also find out if food affects the absorption of cariprazine into the bloodstream after a 'slow release' tablet.
Gedeon Richter Plc. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cariprazine prolonged release tablet B - fed
Drug: Cariprazine PR tablet B
Cariprazine prolonged release tablet A - fed
Drug: Cariprazine PR tablet A
Cariprazine capsule - fasted
Drug: Cariprazine capsule
Cariprazine prolonged release tablet B - fasted
Drug: Cariprazine prolonged release tablet B
Cariprazine prolonged release tablet A - fasted
Drug: Cariprazine prolonged release tablet A
Cariprazine prolonged release tablet A - fasted
Cariprazine prolonged release tablet B - fasted
Cariprazine capsule - fasted
Cariprazine Prolonged Release tablet A - fed
Cariprazine Prolonged Release tablet B - fed
C[max]
Maximum Serum Concentration of the parent drug
Time frame: 0-672 hours
AUC
Area Under the Serum Concentration-Time Curve of the parent drug
Time frame: 0-672 hours
T[max]
Time to Reach the Maximum Serum Concentration of the parent drug
Time frame: 0-672 hours
Other PK parameters of the parent drug
Elimination half-life period (t1/2), Mean Residence Time (MRT), if applicable
Time frame: 0-672 hours
PK parameters of the metabolites, if applicable
Maximum Serum Concentration (Cmax), Time to Reach the Maximum Serum Concentration (Tmax), (AUC0-t), Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC0-∞), Elimination half-life period (t1/2) and Mean Residence Time (MRT)
Time frame: 0-672 hours
The record gives a start of Jun 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine
Gedeon Richter Plc.